Have you ever considered trading biotech stocks? The biotech sector has a reputation for offering risky, but potentially extremely lucrative investing opportunities in relatively short time periods.

Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds. Unlock your all-in-one trading dashboard with ...

On the last trading day of 2025, Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

Legal restrictions on insider trading have been evolving continuously for the last 100 years and are fraught with grey areas. Traders today are able to exploit several major loopholes in order to ...

Why do CEOs talk like that? Do biotech stock tips make good gifts? And what do Anthony Fauci and Stéphane Bancel have in common? We cover all that and more this week on “The Readout LOUD,” STAT’s ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Trading of Shanghai Henlius Biotech, Inc.’s H shares has been temporarily halted as of 9:00 a.m. on May 23, 2024, in ...

09:59 EDT Anbio Biotechnology (NNNN) trading halted, volatility trading pause Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an $41 million insider trading and stock manipulation scheme that involves two biotech ...